Navigation Links
Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression

COPENHAGEN, Denmark, June 04, 2007 /PRNewswire/ --

- Cipralex Better Tolerated and at Least as Effective in Long-Term Treatment

H. Lundbeck A/S announces new study data published today in the journal Current Medical Research and Opinion, demonstrating that Cipralex(R) (escitalopram) was superior to duloxetine in the acute treatment of patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment(1). The study directly compared Cipralex(R) (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (the most recently introduced serotonin and noradrenaline reuptake inhibitor - SNRI) and these findings support the growing body of evidence that Cipralex(R) offers important treatment advantages over SNRI antidepressants such as duloxetine(2-6).

Depression is a serious illness that results in significant disability and is associated with both increased morbidity and the risk of suicide(7). Affecting around 121 million people globally(8,) the World Health Organization lists depression as the leading cause of disability worldwide(8). At present, there is no simple universal treatment effective for all patients and it is therefore relevant that treatments are directly compared in order to provide clinicians with information on the efficacy and tolerability benefits of the currently available treatments.

"The study demonstrates that Cipralex(R) was superior to duloxetine during acute treatment and at least as effective in long-term treatment with the added benefit of significantly better tolerability," said Dr Alan Wade, lead investigator and medical director of CPS Research, Glasgow, Scotland. "Data that compares antidepressants in this way is an important tool for physicians and allows them to make informed decisions about the best treatments for their patients."

Important key findings from the study:

The 24-week study investigated t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

Post Your Comments:
(Date:11/6/2009)...ANGLE PARK, N.C., Nov. 6 Chimerix,...y-available antiviral therapeutics to address life...velopment of the company,s lead antiviral compound...nd the Global Health Security Initiative (GHSI). ...eveloped for the treatment of smallpox, as well as...
(Date:11/6/2009)...ov. 6 California American Water ha...rugs Down the Drain" week for its San Diego County...ored by public and private agencies alike toward t...tion in our source water supplies. ,, Californi...encouraged to drop off expired or unwanted pharmac...
(Date:11/5/2009)...rio, Nov. 5 Helix BioPha...ed today that its Phase II trial of Topical Interf...ts (AGW) has completed patient enrollment, with th...rial. ,, The double-blind and placebo-controlle...n Germany and Sweden. Patients participating in t...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 1Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 2Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 3Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 4Letter to Shareholders From Imagenetix Inc President CEO William Spencer 4902 5A better test to detect DNA for diagnosing diease investigating crimes 55405 1Rutgers Camden developing enzyme function database 9702 1Rutgers Camden developing enzyme function database 9702 2
... FRANCISCO, Calif., July 9 Portola,Pharmaceutical...cused on,the discovery and development of novel th...eases, announced today that is has raised $60 mill...be used primarily to advance,Portola,s two lead an...RT060128, which the company is developing as best-...
... FRANCISCO, July 9 Cerimon Pharmaceuticals,Inc., ...of-concept study of,Simulect(R) (basiliximab) for ...and potentially sight-threatening inflammation of ...ntrolled study will evaluate the,safety and effica...ts.,During the study, patients will undergo taperi...
Other Medicine Technology:Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 2Portola Completes $60 Million Financing to Advance Its Therapeutic Programs 3Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis 2
(Date:11/8/2009)...lutions is pleased to announce that it has been su...or ReSound who recently received an award on the $...ward includes not only the Veterans Administration...eral agencies. , New York...ns is pleased to announce that it has been success...
(Date:11/8/2009)...battle is won," said Dr. Charmaine Yoest. ,, W...vote of 240-194, the Stupak-Ellsworth-Pitts-Kaptur...bortion mandates and funding in HR 3962 passed on ...ction President and CEO Dr. Charmaine Yoest said, ...e pro-life Americans across this country who have ...
(Date:11/8/2009)...SNewswire/ -- The following was released today by ...ta Nex. ,, Mr. Terry and his associates from a...-killing by abortion out of any health care bill f...t first step to victory -- a touchdown in the firs...f us. Our rejoicing must be tempered by reality. T...
(Date:11/7/2009)...SNewswire/ -- Karen Ignagni, President and CEO of ...the following statement today on House passage of ...mprehensive health care reform, and we have contri...verhaul of how health insurance is provided. Earli...mination of pre-existing condition exclusions, no ...
(Date:11/7/2009)...Calling this a "defining moment" for the American ...mes Rohack, M.D., today addressed medical students...specialty societies at the opening of the AMA,s se...em reform will top the agenda. ,, (Logo: http... ) ,, "Over the next 72 hours, this AMA House o...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2
...arhers have found from a long-term study that men ...s more likely to eventually develop Parkinson's di... of Biostatistics and Statistics at the University...tipation is defined as less than one bowel movemen...
...sure to sunlight may increase the risk of developi... a cloudy or opaque area in the normally transpare...vents light rays from passing through the lens and...d people who were exposed to high levels of sunlig...
...of the leading pharmaceutical industries, Ranbaxy ...-market Ranbaxy’s once-a-day formulation of Ciprof...g Controller General of India’s (DCGIs) approval f... around Rs 310 crore. // Ciprofloxacin is the...
...ing men are at greater risk of developing heart di...earchers.Their findings were published in the Arch...ng relationship" between coronary heart disease an...9% increased chance of getting heart disease. Comp...
...he biggest breakthrough, the incidence of the dise...ation of drugs that keeps blood pressure in check.... years in many countries showed that strokes were ... and heart attacks and consequently deaths. The dr...
...e are many grueling and expensive options to explo... of it being Acupuncture. According to an art... are particularly favour acupuncture because they ...s, hundreds are lost with each menstrual cycle and...
Other Medicine News:
AxSYM
ADVIA Centaur Immunoassay System
...linical system combines market-leading chemistry a...y testing capabilities, innovative data management...m. After tests are performed, critical results are...nce. If reflex tests are necessary based on user d...
Miltex frazier ferguson suction tubes
Medicine Products: